Surgical Innovations Group PLC Future board change (8400K)
07 January 2021 - 6:00PM
UK Regulatory
TIDMSUN
RNS Number : 8400K
Surgical Innovations Group PLC
07 January 2021
Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Future board change
Surgical Innovations Group plc (AIM: SUN) the designer,
manufacturer and distributor of innovative medical technology for
minimally invasive surgery ("MIS"), announces that Adam Power,
Group Development Director, has provided twelve months' notice to
the Board that he wishes to retire from his executive role as Group
Development Director, with effect from 31 December 2021. The
current intention is that he will subsequently continue to serve as
a Non-executive Director for a further twelve months until 31
December 2022.
Commenting on the transition, Nigel Rogers, the Company's
Chairman, said: "We are grateful to Adam for both his past and
continuing commitment. These arrangements ensure that Adam can
continue to devote his full commitment to current sales activities
and supporting strategic business development, whilst allowing the
Company sufficient time to manage a smooth transition in his Board
and executive responsibilities."
For further information please contact:
Surgical Innovations Group plc www sigroupplc com
David Marsh, CEO Tel: 0113 230 7597
Charmaine Day, Co Sec & GFC
N+1 Singer (Nominated Adviser & Tel: 020 7496 3000
Broker)
Aubrey Powell (Corporate Finance)
Rachel Hayes (Corporate Broking)
Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and
distribution of innovative, high quality medical products,
primarily for use in minimally invasive surgery. Our product and
business development is guided and supported by a key group of
nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access
systems, surgical instruments and retraction devices which are sold
directly in the UK home market through our subsidiary, Elemental
Healthcare, and exported widely through a global network of trusted
distribution partners. Many of our products in this field are based
on a "resposable" concept, in which the products are part
re-usable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive
against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group
of specialist products employed in laparoscopy, bariatric and
metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully
selected OEM partners, and have also collaborated with a major UK
industrial partner to provide precision engineering solutions to
complex problems outside the medical arena.
We aim for our brands to be recognised and respected by
healthcare professionals in all major geographical markets in which
we operate and provide by development, partnership or acquisition a
broad portfolio of cost effective, procedure specific surgical
instruments and implantable devices that offer reliable solutions
to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two
sites in the UK. Product design, engineering and manufacturing are
carried out at the SI site in Yorkshire. Commercial activities
including marketing, UK distribution and international sales and
marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses are available on the
following websites:
www.sigroupplc.com
www.surginno.com
www.elementalhealthcare.co.uk
To receive regular updates by email, please contact
si@walbrookpr.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAXFKELKFEFA
(END) Dow Jones Newswires
January 07, 2021 02:00 ET (07:00 GMT)
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Apr 2024 to May 2024
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From May 2023 to May 2024